Karyopharm to Serve as Stalking Horse Bidder in Merger
A SEC filing says Karyopharm Therapeutics will serve as stalking horse bidder for a merger with a reorganized company.
Related stories
Foremost Forms Two Joint Ventures and Issues Warrants to Denison
Foremost will receive $650,000 in proceeds and retain a 20% interest in the GR and Blackwing properties, with a six-month grace period for initial joint-venture expenditures.
M impact | MNA | Nov 03, 2026, 12:32 PM UTC
Archimed Completes Acquisition of Standard BioTools Microfluidics Business
Archimed completed its acquisition of Standard BioTools' microfluidics business, now Biomark Scientific.
M impact | MNA | Nov 03, 2026, 12:30 PM UTC
Marathon Petroleum, MPLX to Sell Refineries and Midstream Assets for $4.2 Billion
Marathon Petroleum and MPLX agreed to sell two refineries and midstream assets to CVR Energy for $4.2 billion.
M impact | MNA | Nov 03, 2026, 12:22 PM UTC
Merck Sells US Contract Manufacturing Business to Lonza
Germany's Merck Group is selling its US contract development and manufacturing business to Swiss firm Lonza.
M impact | MNA | Nov 03, 2026, 12:09 PM UTC
EQT-Backed SatPort Infrastructure Completes Speedcast Teleport Acquisition
The acquisition adds 12 teleports across five continents, expanding SatPort Infrastructure’s satellite ground infrastructure platform.
M impact | MNA | Nov 03, 2026, 12:04 PM UTC
Authentic Brands Group Completes Acquisition of Lee
Authentic Brands Group completed its acquisition of Lee.
M impact | MNA | Nov 03, 2026, 12:03 PM UTC